A cannabinoid-based 

biopharmaceutical company.

 

We are focused on drug discovery & personalized medicine derived from plant-based therapeutics and combination therapies.

The new frontier between medicine and botany.

1

AWARDED PATENT INHIBITING AUTOPHAGY TO PREVENT & TREAT CANCER

11

PROVISIONAL PATENT TO TREAT 11 CNS-RELATED VIRUSES & DISEASES*

15

15+ CELL STUDIES  ONCOLOGY & ANTIVIRAL / CNS-RELATED VIRUSES & DISEASES 

OUR PIPELINE

Screen Shot 2018-08-20 at 5.41.55 AM.png

Clinical Trial

DCIS Breast Cancer & Cannabinoids

First & only company to be awarded a patent that includes using any molecule, including cannabinoids, as an autophagy inhibitor.  Several cell studies and clinical trial with live breast cancer patients. 

ONGOING - PHASE I / II

Screen Shot 2018-08-20 at 5.50.44 AM.png

Clinical Trial

HIV Associated Dementia & Cannabinoids

Several cell studies on the use of cannabinoids to treat HIV affiliated dementia  and other central nervous system (CNS) diseases and viruses.

ONGOING - PHASE I / II

Screen Shot 2018-08-20 at 5.55.07 AM.png

Pre-Clinical

Anti-viral Studies to Treat Sepsis

Pre-clinical ant-viral research includes COVID related Sepsis work within a BSL-3 laboratory managed by George Mason University.  Focused on using synthetic cannabinoid-based therapeutics to treating Sepsis and infectious diseases.

ONGOING

 

MEET TARGETED PHARMACEUTICALS 

OUR VISION

Our goal is to bring precision medicine and real science to the cannabis industry by linking the molecular structure of humans to cannabinoid compounds.

DATA DRIVEN SOLUTIONS

Technology and data are at the core of what we do.  We are very much a data-driven technology company focused on using data for personalized cannabinoid care.     

 

TOP TEAM & ADVISORS FROM 

Screen Shot 2018-08-20 at 12.31.09 AM.pn
Screen Shot 2018-08-20 at 12.32.02 AM.pn
Screen Shot 2018-08-20 at 12.31.44 AM.pn
Screen Shot 2018-08-20 at 12.32.31 AM.pn
AlanCarpino.png
LanceLiotta.png
JaretChristopher.png
 

TOP TEAM & ADVISORS FROM 

George Mason University

National Cancer Institute

Harvard University 

Worcester Polytechnic Institute

McLean Hospital

Food & Drug Adminstration

LATEST NEWS

Oct 22, 2020

Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

  • Targeted Pharmaceuticals, Tetra Bio-Pharma and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
     

  • ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that it has signed a research collaboration agreement with Targeted Pharmaceutical and the George Mason University.  The research is being conducted at the Biomedical Research Laboratory (BRL) which is managed by the George Mason University National Center for Biodefense and Infectious Diseases (NCBID)

Julu 23, 2019

George Mason University Patent with Applications to Breast Cancer Treatment Licensed by Targeted Pharmaceuticals, a Cannabinoid-Based Drug Discovery Company

Manassas, Va. – A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of  oncology and central nervous system disorders.

The patent, secured by faculty members of George Mason University’s Institute for Biohealth Innovation and licensed by Targeted Pharmaceuticals, covers autophagy inhibitors as therapeutic compounds. The intellectual property was cultivated through a completed Phase 1/2 window trial for breast ductal carcinoma in situ (DCIS). The trial was conducted in collaboration between Drs. Virginia Espina and Lance Liotta of George Mason University, and Dr. Kirsten Edmiston of Inova Health System (PINC trial, clinicaltrials.gov identifier NCT01023477).

“The results of the PINC trial made it clear that our discovery had the potential to treat breast cancer before it spreads,” said Liotta, Co-Director & Co-Founder of the Center for Applied Proteomics and Molecular Medicine and professor at George Mason University’s College of Science.

In many conditions, such as neurodegenerative diseases, cancers, infectious diseases, and metabolic conditions, autophagy goes awry. In cancer especially, it can be a double-edged sword: it can suppress tumors by initiating cell death after exposure to cancer therapies, or it can actually help the cancer cells survive by allowing the recycling of cellular components to provide energy during severe stress. 

Espina, a science research associate professor of the Center for Applied Proteomics and Molecular Medicine, has been investigating autophagy pathways for several years. “When we first started, it was under-appreciated that autophagy was used as a survival mechanism and not just a mechanism of cell death,” Espina said. Her team realized that if the autophagy pathway was interrupted, it could cause the cancer cells to die.

 

GET

IN TOUCH

Targeted Pharmaceuticals
11 Apex Drive, Suite 300A
Marlborough, MA 01752
Screen Shot 2021-03-04 at 10.58.07 AM.pn
Targeted-Pharmaceuticalsl-logo-black.png

Targeted Pharmaceuticals is a cannabinoid-based drug discovery company.

Contact us today to learn more. 

Success! Message received.

 
Targeted-Pharmaceuticals-logo4.png